Applies to Medicaid plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Adult initial approval for T2DM (non-preferred product)
All of:
- Age ≥ 18 years
- Documented diagnosis of T2DM
- Trial and failure (e.g., A1C goal not met), intolerance, or contraindication to metformin (90-day lookback for paid claims in history)
- Documentation of baseline A1C within the previous 3 months
- Requested dose does not exceed the maximum FDA-approved dose for treatment of diabetes mellitus
- Trial and failure of at least one preferred product (Ozempic, Trulicity, or Victoza), OR rationale as to why preferred products cannot be used
Documentation to bring
- Documented diagnosis of T2DM
- Evidence of metformin trial and failure, intolerance, or contraindication (90-day lookback for paid claims in history)
- Baseline A1C lab result within the previous 3 months
- Confirmation that requested dose does not exceed maximum FDA-approved dose for diabetes
- Documentation of trial and failure of a preferred product (Ozempic, Trulicity, or Victoza), OR clinical rationale why preferred products cannot be used
Approval and renewal
- Initial approval: 6 months
- Renewal: every 12 months
- Renewal: Improvement in A1C.
- Renewal: Reduction in A1C from baseline, OR A1C goal achieved, OR improvement in fasting blood glucose levels. Supporting documentation within the previous 3 months required. Patient must not have experienced any treatment-restricting adverse events.
Policy note: Mounjaro is listed under 'Other Products' and is a non-preferred agent. It requires the same base criteria as preferred products (Ozempic, Trulicity, Victoza) PLUS a trial or failure of a preferred product, or rationale for why preferred products cannot be used. The document does not explicitly state that prior glp1_trial duration must meet a specific threshold — only that a trial and failure occurred. The document does not address Mounjaro for weight loss indication at all; no entry emitted for that.
Policy effective May 1, 2026 · verified June 4, 2026 · source: Sc Rx P Acriteria Glp1s · View policy document (PDF)